Pörssitiedote30.09.2024 klo 15.30Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)
Pörssitiedote16.09.2024 klo 16.30Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Pörssitiedote03.09.2024 klo 13.15Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Pörssitiedote03.09.2024 klo 13.00Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Pörssitiedote13.08.2024 klo 08.00Calliditas Therapeutics: Calliditas Interim Report January to June 2024
Lehdistötiedote05.08.2024 klo 08.00Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024
Lehdistötiedote26.07.2024 klo 18.00Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Pörssitiedote26.07.2024 klo 09.00Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Lehdistötiedote04.07.2024 klo 09.30Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Lehdistötiedote18.06.2024 klo 13.15Calliditas Therapeutics: Calliditas provides setanaxib patent update
Pörssitiedote17.06.2024 klo 18.30Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Pörssitiedote30.05.2024 klo 21.00Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Lehdistötiedote28.05.2024 klo 15.00Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Pörssitiedote28.05.2024 klo 09.30Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation